International Stem Cell CORP Operating Income

Quick Answer

International Stem Cell CORP reported Operating Income of -$267.0 thousand for fiscal year 2025.

International Stem Cell CORP Operating Income — Annual History

Fiscal Year Operating Income YoY Change
2025 -$267.0K -292.6%
2024 -$68.0K +89.7%
2023 -$663.0K -262.3%
2022 -$183.0K +90.5%
2021 -$1.92M +31.8%
2020 -$2.82M +50.8%
2019 -$5.73M -64.9%
2018 -$3.47M +29.7%
2017 -$4.94M -1.9%
2016 -$4.85M -6.3%
2015 -$4.56M +47.4%
2014 -$8.68M -15.0%
2013 -$7.55M +23.1%
2012 -$9.81M +13.6%
2011 -$11.36M -8.5%
2010 -$10.46M

Quarterly Operating Income

Quarter Ending Operating Income YoY QoQ
September 30, 2025 $94.0K +204.4% -43.7%
June 30, 2025 $167.0K +12.1% +177.7%
March 31, 2025 -$215.0K -20.8% -138.9%
September 30, 2024 -$90.0K +7.2% -160.4%
June 30, 2024 $149.0K +203.5% +183.7%
March 31, 2024 -$178.0K -9000.0% -83.5%
September 30, 2023 -$97.0K +67.7% +32.6%
June 30, 2023 -$144.0K -564.5% -7300.0%
  • International Stem Cell CORP showed a decrease of -292.6% in Operating Income compared to the prior fiscal year.
  • Over the 2010–2025 period, International Stem Cell CORP’s operating income has grown by 97.4% (from -$10.46 million to -$267.0 thousand).
  • The most recent figure is from International Stem Cell CORP’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment